Fox2Now St. Louis

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
Finanznachrichten

Amgen's Repatha Cuts Risk Of First Major Adverse Cardiovascular Events By 25% In Landmark Phase 3 Vesalius-cv Trial

Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif., Nov. 8, ...
Seeking Alpha

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...
Investing

FDA expands Repatha approval for adults with high LDL cholesterol

THOUSAND OAKS, Calif. - The U.S. Food and Drug Administration has broadened the approved use of Amgen’s (NASDAQ:AMGN) Repatha to include adults at increased risk for major adverse cardiovascular ...
Morningstar

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Investing

Amgen’s Repatha reduces CV events in patients without prior heart attack

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a biotechnology giant with a market capitalization of $157.2 billion and 12.88% revenue growth over the last twelve months, announced Friday that its ...